Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $201.9K | $116.8K | $111.5K | $193.3K | $209.9K |
| Gross profit | $0 | $0 | −$201.9K | −$116.8K | −$111.5K | −$193.3K | −$209.9K |
| Gross margin | — | — | — | — | — | — | — |
| R&D | $3.2M | $6.6M | $2.9M | $859.8K | $9.7M | $17.2M | $27.9M |
| Operating income | −$5.0M | −$14.3M | −$6.1M | −$2.2M | −$20.9M | −$22.6M | −$37.9M |
| EBITDA | −$4.9M | −$14.2M | −$5.1M | −$1.8M | −$20.8M | −$22.4M | −$37.4M |
| Net income | −$4.3M | −$13.2M | −$7.2M | −$4.0M | −$23.0M | −$23.3M | −$38.1M |
| Net margin | — | — | — | — | — | — | — |
| EPS (diluted) | -0.34 | -1.03 | -0.56 | -0.31 | -1.61 | -1.21 | -1.58 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $45M | $-0.44 | $-0.44–$-0.44 | 1 |
| 2027 | $80M | $0.33 | $0.33–$0.33 | 1 |
| 2028 | $32M | $-0.37 | $-0.37–$-0.37 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds EPRXF.
No tracked institution reports a position in EPRXF as of their last filing.
No one on the platform has traded EPRXF yet.
| — |
| $109M |
| — |
| ETXPFE-therapeutics Plc | $0.13 | +0.00% | $76M | — |
| HRPMFHerantis Pharma Oyj | $3.51 | +0.00% | $59M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.